In vitro activity of the semisynthetic glycopeptide amide MDL 63,246.
The in vitro activity of the semisynthetic glycopeptide amide MDL 63,246 against 293 U.S. clinical isolates of gram-positive cocci was determined by the broth microdilution method. When compared with teicoplanin, MDL 63,246 had improved activity against Staphylococcus epidermidis (MICs that inhibited 90% strains tested [MIC90s], 0.25 versus 8 micrograms/ml, respectively). Staphylococcus haemolyticus (MIC90s, 1 versus 32 micrograms/ml, respectively), and VanA Enterococcus faecium (MIC90s, 32 versus > or = 1,024 micrograms/ml, respectively).
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D006095:Gram-Positive Cocci / Q000187:drug effects*; D008826:Microbial Sensitivity Tests; D017334:Teicoplanin / Q000031:analogs & derivatives / Q000494:pharmacology; D014640:Vancomycin / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D017334:Teicoplanin; D014640:Vancomycin; C096602:MDL 63246